MENAs Silent Killer: Cardiometabolic Diseases Claim 1.4 Million Lives Annually, Urgent Call for Global Health Action
In the Middle East and North Africa (MENA), cardiovascular disease and diabetes together claim an estimated 1.4 million and 796 000 lives each year, a figure that accounts for 74 % of all deaths in the region. The new analysis shows that non‑communicable diseases (NCDs) now eclipse warfare and terrorism as the leading cause of mortality.
The toll extends beyond the elderly. Nearly 38 % of people with diabetes in MENA remain undiagnosed, meaning many families confront costly, lifelong treatment only after complications arise. The economic burden of diabetes alone is projected to reach $1.5 trillion annually by 2050, encompassing direct medical costs and indirect losses such as reduced productivity.
Health‑system gaps are a major driver of the crisis. The report notes that many countries lack preventive‑care structures, educational programs, and robust surveillance systems. Without early detection and lifestyle interventions, patients often need expensive medication and specialist care, placing a heavy financial strain on families and national budgets.
The World Health Organization (WHO) recommends a set of cost‑effective “best‑buy” interventions for NCDs, including measures to reduce smoking, alcohol consumption, unhealthy diets, and sedentary behaviour. A recent investment case for Gulf Cooperation Council (GCC) countries found that scaling up these interventions would generate a return of $4.90 for every $1 invested, potentially averting roughly 290 000 premature deaths.
The authors argue that political will to tackle cardiometabolic diseases is currently insufficient. They call for a coordinated approach that mirrors the global response to infectious disease outbreaks and national security threats. The report points to the President’s Emergency Plan for AIDS Relief (PEPFAR) as a model, noting that the program has saved an estimated 25 million lives through sustained political commitment, funding, and partnership.
Roche, a global pharmaceutical company, supports the analysis. While the report is authored independently, the partnership underscores the potential for public‑private collaboration to accelerate prevention, early detection, and treatment of cardiometabolic conditions.
Regional implications are significant. Cardiometabolic diseases strain health systems already stretched by conflict, migration, and economic volatility. The high prevalence of these conditions can undermine workforce productivity, increase health‑care costs, and widen social inequities.
International cooperation is also essential. The analysis stresses that a global coalition of governments, pharmaceutical companies, medical device manufacturers, payers, providers, and citizens is needed to mobilise resources, share best practices, and implement evidence‑based interventions across borders.
In short, the MENA region faces a preventable catastrophe that demands the same urgency and coordination applied to infectious disease outbreaks. The data show that strategic investments in prevention, surveillance, and treatment can yield substantial health and economic benefits. The next steps will require sustained political commitment, cross‑sector collaboration, and a willingness to adopt proven global health models.
The situation remains urgent. Without decisive action, the region risks a continued rise in cardiometabolic mortality, escalating health‑care costs, and further destabilisation of already fragile health systems.
